CRIS Current Research Information System

MARTELLO, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.528
NA - Nord America 2.830
EU - Europa 2.097
AF - Africa 251
SA - Sud America 174
OC - Oceania 3
Totale 8.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.780
VN - Vietnam 1.121
CN - Cina 853
SG - Singapore 830
IT - Italia 676
GB - Regno Unito 300
DE - Germania 242
HK - Hong Kong 213
SE - Svezia 189
IN - India 151
NL - Olanda 132
FR - Francia 130
BR - Brasile 122
KR - Corea 114
RU - Federazione Russa 88
CI - Costa d'Avorio 86
IE - Irlanda 72
FI - Finlandia 55
JP - Giappone 45
SC - Seychelles 43
TG - Togo 41
ZA - Sudafrica 37
PH - Filippine 32
BD - Bangladesh 30
BG - Bulgaria 28
AT - Austria 27
CH - Svizzera 27
AR - Argentina 25
CA - Canada 25
UA - Ucraina 25
NG - Nigeria 23
PL - Polonia 22
EE - Estonia 20
MX - Messico 19
TH - Thailandia 19
ES - Italia 18
ID - Indonesia 18
BE - Belgio 17
TW - Taiwan 14
JO - Giordania 12
IQ - Iraq 11
TR - Turchia 11
IR - Iran 10
EC - Ecuador 9
SA - Arabia Saudita 8
RO - Romania 7
CO - Colombia 6
DZ - Algeria 5
CL - Cile 4
CY - Cipro 4
CZ - Repubblica Ceca 4
PK - Pakistan 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
HR - Croazia 3
LT - Lituania 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
UZ - Uzbekistan 3
VE - Venezuela 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
PS - Palestinian Territory 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
AL - Albania 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
QA - Qatar 1
TZ - Tanzania 1
ZW - Zimbabwe 1
Totale 8.883
Salva come PNG Salva come JPEG
Città #
Singapore 573
Ashburn 356
Ho Chi Minh City 311
Chandler 275
Southend 243
Hanoi 240
Hefei 240
Hong Kong 208
Dallas 193
Fairfield 188
Bologna 167
San Jose 160
Ann Arbor 121
Seoul 108
Beijing 97
Abidjan 86
Houston 82
Woodbridge 78
Wilmington 77
Dublin 72
Seattle 69
Cambridge 67
Princeton 66
New York 60
Lauterbourg 53
Los Angeles 53
Milan 52
Santa Clara 50
Boardman 47
Haiphong 44
Helsinki 43
Lomé 41
Hyderabad 39
Dong Ket 38
Tokyo 37
Munich 36
Bremen 31
Nanjing 31
Da Nang 27
Fabriano 27
Sofia 27
Frankfurt am Main 26
Amsterdam 24
Westminster 23
Bengaluru 22
Buffalo 22
Turin 22
Abeokuta 20
Berlin 20
Padova 20
Salsomaggiore Terme 20
Vienna 20
Council Bluffs 19
Guangzhou 18
Redmond 18
Rome 18
Biên Hòa 17
Can Tho 17
São Paulo 17
Bern 16
Brussels 16
Warsaw 16
Ha Long 15
Redondo Beach 15
Medford 14
Quận Bình Thạnh 14
Shenyang 14
Nuremberg 13
Shanghai 13
Thái Nguyên 13
Toronto 13
Amman 12
Florence 12
Hải Dương 12
Ninh Bình 12
Redwood City 12
Saint Petersburg 12
Wuhan 12
Falkenstein 11
Jakarta 11
Jinan 11
London 11
Tianjin 11
Changsha 10
Johannesburg 10
Nanchang 10
Quận Một 10
Lappeenranta 9
Mondolfo 9
Orem 9
Zhengzhou 9
Bắc Ninh 8
Bến Tre 8
Dhaka 8
Orlando 8
Paris 8
Brooklyn 7
Chicago 7
Des Moines 7
Hangzhou 7
Totale 5.631
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 291
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 227
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 226
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 220
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 218
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 211
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 207
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 203
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 202
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 197
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 194
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 192
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 189
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 181
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 179
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 175
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 174
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 172
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 172
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 166
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 165
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 165
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 163
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 162
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 154
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 153
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 152
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 149
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 147
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 143
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 143
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 142
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 137
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 135
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 135
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 134
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 130
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 129
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 122
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 111
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts 110
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 103
null 98
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 86
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 81
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 74
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 70
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 52
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 44
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application 24
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? 21
Totale 9.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021121 0 0 0 0 0 0 0 0 0 17 18 86
2021/2022794 73 41 37 62 62 41 27 50 40 99 120 142
2022/20231.073 96 140 47 170 81 80 29 57 157 48 84 84
2023/2024486 39 46 43 39 31 97 26 88 14 19 24 20
2024/20251.363 98 132 112 110 121 61 111 57 30 156 126 249
2025/20264.073 356 963 350 319 367 174 361 166 803 214 0 0
Totale 9.055